ALPHAMAB ONCOLOGY

Analyst Reco. Alphamab Oncology

Equities

9966

KYG0330A1013

Delayed Hong Kong S.E. Other stock markets 10:29:39 2024-06-06 pm EDT			5-day change	1st Jan Change
2.97 ^HKD	+3.12%		+18.11%	-54.82%

Jun. 05	ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment	MT
Jun. 05	Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UBS Adjusts Alphamab Oncology's Price Target to HK$12.94 From HK$13.22, Keeps at Buy	22-09-07	MT
Nomura Adjusts Alphamab Oncology's Price Target to HK$13.22 From HK$13.89, Keeps at Buy	22-04-04	MT
ALPHAMAB ONCOLOGY : Nomura Adjusts Alphamab Oncology's Price Target to HK$28.8 From HK$25.1, Keeps at Buy	21-05-25	MT
ALPHAMAB ONCOLOGY : Nomura Adjusts Alphamab Oncology's Price Target to HK$25.1 From HK$17.2, Keeps at Buy	21-05-12	MT
ALPHAMAB ONCOLOGY : Nomura Starts Alphamab Oncology at Buy With HK$17.2 Price Target	21-01-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer